TY - JOUR
T1 - Practical management of patients with myelofibrosis receiving ruxolitinib
AU - Harrison, Claire
AU - Mesa, Ruben
AU - Ross, David
AU - Mead, Adam
AU - Keohane, Clodagh
AU - Gotlib, Jason
AU - Verstovsek, Srdan
N1 - Funding Information:
C Harrison has received honoraria from Novartis, Sanofi-Aventis, Celgene and Shire; received research funding from Novartis and Shire; acted as a consultant to YM BioSciences, S*BIO, Sanofi-Aventis and Novartis. R Mesa has received research funding from Incyte, NS Pharma, Eli Lilly, Sanofi-Aventis and YM BioSciences. D Ross has received honoraria from Novartis, BMS and Shire; received research funding from Novartis. A Mead has received honoraria from Novartis, Sanofi-Aventis and Shire. C Keohane has received research funding from Novartis. J Gotlib has received honoraria from Incyte and Gilead; received research funding from Incyte, Sanofi-Aventis and Gilead; and acted as a consultant to Incyte and Gilead. S Verstovsek has received hon-oraria from Novartis; has received research fund-ing from Incyte. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
PY - 2013
Y1 - 2013
N2 - Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate-or high-risk MF, and more recently in Europe and Canada for the treatment of MF-related splenomegaly or symptoms. These approvals were based on data from two randomized Phase III studies: COMFORT-I randomized against placebo, and COMFORT-II randomized against best available therapy. In these studies, ruxolitinib rapidly improved multiple disease manifestations of MF, reducing splenomegaly and improving quality of life of patients and potentially prolonging survival. However, as with other chemotherapies, ruxolitinib therapy is associated with some adverse events, such as anemia and thrombocytopenia. The aims of this article are to provide a brief overview of ruxolitinib therapy, to discuss some common adverse events associated with ruxolitinib therapy and to provide clinical management recommendations to maximize patients' benefit from ruxolitinib.
AB - Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate-or high-risk MF, and more recently in Europe and Canada for the treatment of MF-related splenomegaly or symptoms. These approvals were based on data from two randomized Phase III studies: COMFORT-I randomized against placebo, and COMFORT-II randomized against best available therapy. In these studies, ruxolitinib rapidly improved multiple disease manifestations of MF, reducing splenomegaly and improving quality of life of patients and potentially prolonging survival. However, as with other chemotherapies, ruxolitinib therapy is associated with some adverse events, such as anemia and thrombocytopenia. The aims of this article are to provide a brief overview of ruxolitinib therapy, to discuss some common adverse events associated with ruxolitinib therapy and to provide clinical management recommendations to maximize patients' benefit from ruxolitinib.
KW - JAK inhibitor
KW - myelofibrosis
KW - myeloproliferative neoplasms
KW - ruxolitinib
KW - splenomegaly
UR - http://www.scopus.com/inward/record.url?scp=84885906469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885906469&partnerID=8YFLogxK
U2 - 10.1586/17474086.2013.827413
DO - 10.1586/17474086.2013.827413
M3 - Review article
C2 - 24083419
AN - SCOPUS:84885906469
SN - 1747-4086
VL - 6
SP - 511
EP - 523
JO - Expert Review of Hematology
JF - Expert Review of Hematology
IS - 5
ER -